pSivida lines up EMA, FDA applications for eye drug/device as 2nd PhIII delivers positive data
Watertown, MA-based pSivida says their lead eye drug for posterior segment uveitis hit the primary endpoint of their second Phase III trial, putting them on …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
